Series AVenture Capital
Nilo Therapeutics Raises $101M Series A Led by The Column Group, DCVC Bio and Lux Capital
•October 9, 2025
•Oct 9, 2025
Participants
Deal Summary
Nilo Therapeutics, a NYC-based biotech focused on harnessing neural circuits to restore immune homeostasis, closed a $101M Series A. The round was led by The Column Group, DCVC Bio and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments.
Comments
Want to join the conversation?
Loading comments...